These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37031622)

  • 1. Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1 year.
    Mochizuki T; Yano K; Ikari K; Okazaki K
    Respir Investig; 2023 May; 61(3):359-363. PubMed ID: 37031622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis.
    Narváez J; Aguilar-Coll M; Roig-Kim M; Maymó-Paituvi P; Palacios-Olid J; Nolla JM; LLop D
    Autoimmun Rev; 2024 Oct; 23(10):103636. PubMed ID: 39270812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study.
    Tsujii A; Isoda K; Yoshimura M; Nakabayashi A; Kim DS; Tamada T; Yamamoto K; Ohshima S
    BMC Rheumatol; 2024 Jan; 8(1):4. PubMed ID: 38273359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease.
    Tardella M; Di Carlo M; Carotti M; Ceccarelli L; Giovagnoni A; Salaffi F
    Inflammopharmacology; 2022 Jun; 30(3):705-712. PubMed ID: 35462572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.
    Mochizuki T; Ikari K; Yano K; Sato M; Okazaki K
    Mod Rheumatol; 2019 May; 29(3):413-417. PubMed ID: 29798700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease.
    Cronin O; McKnight O; Keir L; Ralston SH; Hirani N; Harris H
    Rheumatol Int; 2021 May; 41(5):921-928. PubMed ID: 33721094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease.
    Lee KA; Kim BY; Kim SS; Cheon YH; Lee SI; Kim SH; Jung JH; Kim GT; Hur JW; Lee MS; Kim YS; Hong SJ; Park S; Kim HS
    Korean J Intern Med; 2024 Sep; 39(5):855-864. PubMed ID: 39252490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
    Fernández-Díaz C; Castañeda S; Melero-González RB; Ortiz-Sanjuán F; Juan-Mas A; Carrasco-Cubero C; Casafont-Solé I; Olivé A; Rodríguez-Muguruza S; Almodóvar-González R; Castellanos-Moreira R; Rodríguez-García SC; Aguilera-Cros C; Villa I; Ordóñez-Palau S; Raya-Alvarez E; Morales-Garrido P; Ojeda-García C; Moreno-Ramos MJ; Bonilla Hernán MG; Hernández Rodríguez I; López-Corbeto M; Andreu JL; Jiménez de Aberásturi JRD; Ruibal-Escribano A; Expósito-Molinero R; Pérez-Sandoval T; López-Robles AM; Carreira-Delgado P; Mena-Vázquez N; Urruticoechea-Arana A; Peralta-Ginés C; Arboleya-Rodríguez L; Narváez García FJ; Palma-Sánchez D; Cervantes Pérez EC; Maiz-Alonso O; Alvarez-Rivas MN; Fernández-Melón J; Vela Casasempere P; Cabezas-Rodríguez I; Castellvi-Barranco I; González-Montagut C; Blanco-Madrigal J; Del Val-Del Amo N; Fito MC; Rodríguez-Gómez M; Salgado-Pérez E; García-Magallón B; Hidalgo-Calleja C; López-Sánchez R; Fernández-Aguado S; Fernández-López JC; Castro-Oreiro S; Serrano-García I; García-Valle A; Romero-Yuste S; Expósito-Pérez L; Pérez-Albadalejo L; García-Aparicio A; Quillis-Marti N; Bernal-Vidal JA; Loricera-García J; Hernández JL; González-Gay MA; Blanco R
    Rheumatology (Oxford); 2020 Dec; 59(12):3906-3916. PubMed ID: 33068439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: A case report.
    Mochizuki T; Yano K; Ikari K; Okazaki K
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):350-353. PubMed ID: 37061836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
    Vicente-Rabaneda EF; Atienza-Mateo B; Blanco R; Cavagna L; Ancochea J; Castañeda S; González-Gay MÁ
    Autoimmun Rev; 2021 Jun; 20(6):102830. PubMed ID: 33887489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.
    Tardella M; Di Carlo M; Carotti M; Giovagnoni A; Salaffi F
    Clin Rheumatol; 2021 Dec; 40(12):4861-4867. PubMed ID: 34313866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
    Fernández-Díaz C; Loricera J; Castañeda S; López-Mejías R; Ojeda-García C; Olivé A; Rodríguez-Muguruza S; Carreira PE; Pérez-Sandoval T; Retuerto M; Cervantes-Pérez EC; Flores-Robles BJ; Hernández-Cruz B; Urruticoechea A; Maíz-Alonso O; Arboleya L; Bonilla G; Hernández-Rodríguez Í; Palma D; Delgado C; Expósito-Molinero R; Ruibal-Escribano A; Álvarez-Rodríguez B; Blanco-Madrigal J; Bernal JA; Vela-Casasempere P; Rodríguez-Gómez M; Fito C; Ortiz-Sanjuán F; Narváez J; Moreno M; López-Corbeto M; Mena-Vázquez N; Aguilera-Cros C; Romero-Yuste S; Ordóñez S; Villa-Blanco I; Gonzélez-Vela MC; Mora-Cuesta V; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
    Semin Arthritis Rheum; 2018 Aug; 48(1):22-27. PubMed ID: 29422324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.
    Nakashita T; Ando K; Kaneko N; Takahashi K; Motojima S
    BMJ Open; 2014 Aug; 4(8):e005615. PubMed ID: 25125479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
    Kurata I; Tsuboi H; Terasaki M; Shimizu M; Toko H; Honda F; Ohyama A; Yagishita M; Osada A; Ebe H; Kawaguchi H; Takahashi H; Hagiwara S; Asashima H; Kondo Y; Matsumoto I; Sumida T
    Intern Med; 2019 Jun; 58(12):1703-1712. PubMed ID: 30799358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
    Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
    Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study.
    Shih PC; Lai CC; Zou QH; Wang SI; Huang XY; Wei JCC
    Clin Exp Med; 2024 Aug; 24(1):186. PubMed ID: 39133368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
    Rojas-Serrano J; Herrera-Bringas D; Pérez-Román DI; Pérez-Dorame R; Mateos-Toledo H; Mejía M
    Clin Rheumatol; 2017 Jul; 36(7):1493-1500. PubMed ID: 28585060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.
    Atienza-Mateo B; Fernández-Díaz C; Vicente-Rabaneda EF; Melero-González RB; Ortiz-Sanjuán F; Casafont-Solé I; Rodríguez-García SC; Ferraz-Amaro I; Castañeda S; Blanco R;
    Eur J Intern Med; 2024 Jan; 119():118-124. PubMed ID: 37673775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study.
    Kang EH; Jin Y; Desai RJ; Liu J; Sparks JA; Kim SC
    Semin Arthritis Rheum; 2020 Jun; 50(3):401-408. PubMed ID: 31813561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.